Related Experiment Videos
Coronary thrombolysis: still too little too late?
Insights
Delays in hospital care and underuse of thrombolytic therapy for myocardial infarction (MI) were common. Treatment improved after the ISIS-2 study, reducing delays and increasing streptokinase use for heart attack patients.
Area of Science:
- Cardiology
- Public Health
Background:
- Myocardial infarction (MI) management requires timely intervention.
- Thrombolytic therapy is crucial for improving outcomes in acute MI.
Purpose of the Study:
- To identify delays in hospital care for myocardial infarction patients.
- To assess the utilization of thrombolytic therapy (streptokinase) and its trends.
Main Methods:
- Retrospective review of 109 consecutive myocardial infarction patient records.
- Analysis of delays in hospital referral, coronary care unit admission, and thrombolysis initiation.
- Comparison of thrombolytic therapy use before and after the ISIS-2 study publication.
Main Results:
- Only 26% of patients received streptokinase, with 58% of eligible patients not receiving it.
- Average delay from symptom onset to hospital presentation exceeded 3 hours.
- A further 1-hour in-hospital delay occurred before thrombolysis administration.
- Streptokinase use significantly increased post-ISIS-2 study publication.
Conclusions:
- Significant underuse of indicated thrombolytic therapy for myocardial infarction was observed.
- Hospital care delays contributed to suboptimal treatment.
- Audit and study results led to substantial improvements in thrombolytic therapy administration.
Abstract:
We reviewed the case records of 109 consecutive patients with a definite diagnosis of myocardial infarction, admitted through the accident and emergency department of an inner-city general hospital to identify delays in referral to hospital, admission to the coronary care unit, and start of thrombolysis. Of the 109 patients, only 28 (26%) received streptokinase (the only thrombolytic drug used at this hospital), and at least 47 (58%) of the remaining 81 who should have benefited from it did not. However, the proportion of patients given streptokinase improved significantly after publication of the Second International Study of Infarct Survival (ISIS 2) study results. The average delay from onset of symptoms to presentation at the accident department was over 3 hours, with a further 1 hour in-hospital delay before administration of streptokinase. This study revealed considerable underuse of thrombolytic therapy in cases where treatment was clearly indicated, but this picture improved substantially during the period of audit.